中药治疗肠易激综合征:随机对照试验的Meta分析与试验序贯分析
该Meta分析与试验序贯分析纳入10项随机对照试验共2501例肠易激综合征患者,评估中药的疗效与安全性。结果显示,与安慰剂相比,中药显著提高整体症状充分缓解率(RR 1.76,95%CI 1.33-2.33)和腹痛缓解率(RR 1.85,95%CI 1.59-2.14),但不良事件发生率也更高(RR 1.51,95%CI 1.14-2)。试验序贯分析确认信息量充足。
要点
- 中药可显著提高IBS整体症状充分缓解率,但异质性较高(I²=81.1%)。
- 中药缓解腹痛的效应一致(I²=0%),且信息量充足。
- 中药相关不良事件发生率高于安慰剂,需关注安全性。
核心结论
- 中药对缓解肠易激综合征症状有效,但不良事件发生率高于安慰剂。
- 试验序贯分析确认主要结局信息量充足,结论稳健。
研究设计与样本
- 研究为Meta分析与试验序贯分析,检索OVID Medline、Embase、Cochrane Central Register of Controlled Trials和Web of Science(1980年1月1日至2020年9月20日)。
- 共纳入10项随机对照试验,2501例肠易激综合征患者,其中7项(70%)为低偏倚风险。
主要发现
- 与安慰剂相比,中药组整体症状充分缓解率显著更高(RR 1.76,95%CI 1.33-2.33;I²=81.1%;p<0.001),所需信息量(RIS)为1083,实际累积信息量为1716。
- 腹痛缓解分析纳入3项试验共916例,中药组优于安慰剂(RR 1.85,95%CI 1.59-2.14;I²=0%;p<0.001;RIS=197)。
- 中药组不良事件发生率高于安慰剂组(RR 1.51,95%CI 1.14-2;I²=0%;p=0.004)。
关键数值与推荐
- 主要结局为整体IBS症状充分缓解,次要结局包括腹痛缓解和治疗相关不良事件。
- 效应量以相对危险度(RR)及95%置信区间表示,并计算所需信息量(RIS)。
临床怎么用
- 临床可考虑中药作为IBS的补充替代治疗以缓解整体症状和腹痛。
- 使用中药时需监测不良事件,权衡获益与风险。
局限性
- 主要结局异质性较高(I²=81.1%),可能影响结果解释。
- 纳入试验数量有限(10项),部分结局分析仅基于3项试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: Chinese herbal medicine (CHM) is an important complementary and alternative therapy for the management of irritable bowel syndrome (IBS). Previous meta-analyses suggested that CHM is effective for IBS; nonetheless, its effectiveness is inconclusive owing to repeated significance testing. We aimed to examine the efficacy and safety of CHM for IBS through a meta-analysis and trial sequential analysis (TSA). Methods: We searched OVID Medline, Embase, Cochrane Central Register of Controlled Trials, and Web of Science from January 1, 1980, to September 20, 2020. The primary outcome was adequate relief of global IBS symptoms. The secondary outcomes included relief of abdominal pain and treatment-related adverse events. The relative ratio (RR) and required information size (RIS) were calculated for each outcome. Results: Ten trials recruiting 2,501 participants were included. Seven (70%) trials were at low risk of bias (RoB). Compared with placebo, CHM was associated with a significantly higher proportion of adequate relief of global IBS symptoms [RR 1.76 (95% confidence interval (95%CI), 1.33-2.33); I 2 = 81.1%; p < 0.001]. The RIS was 1,083 for the primary outcome, and the accrued information size was 1,716. The analysis of the relief of abdominal pain (three trials with 916 participants) showed similar results compared with placebo [RR 1.85 (95%CI, 1.59-2.14); I 2 = 0%; p < 0.001; RIS = 197 participants]. CHM was associated with a higher proportion of adverse events compared with placebo [RR 1.51 (95%CI, 1.14-2); I 2 = 0%; p = 0.004]. Conclusion: CHM was effective in relieving IBS symptoms but caused a higher adverse event rate than placebo. TSA analysis confirmed the findings with sufficient information size.
引用
- Zheng H, Jin S, Shen YL, et al. Chinese Herbal Medicine for Irritable Bowel Syndrome: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Front Pharmacol. 2021. PMID: 34385918. doi:10.3389/fphar.2021.694741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。